Background Higher consumption of coffee and tea has been associated with improved health outcomes in the general population and improved breast cancer (BC) prognosis. This study investigated patterns of coffee and tea consumption and association with patient-reported outcomes (PROs) and clinical outcomes among survivors of BC. Methods The...
-
2022 (v1)PublicationUploaded on: February 14, 2024
-
January 2017 (v1)Journal article
To investigate whether adding bevacizumab to neoadjuvant carboplatin-paclitaxel (CP) helps achieve optimal debulking, measured by complete resection rate (CRR) at interval debulking surgery (IDS), in patients with initially unresectable International Federation of Gynecology and Obstetrics stage IIIC/IV ovarian, tubal or peritoneal adenocarcinoma.
Uploaded on: February 28, 2023 -
May 20, 2021 (v1)Journal article
1064 Background: In 11.2018, the PIK3CA-inhibitor alpelisib was made available in France through an early access program (EAP), in combination with fulvestrant in pre-treated PIK3CA-mutant, HR-positive, HER2-negative advanced breast cancer (ABC) patients. Patients had to received two or more prior systemic treatments for ABC, including an...
Uploaded on: December 3, 2022 -
November 16, 2023 (v1)Journal article
IMPORTANCE Younger survivors of breast cancer frequently report more treatment-related symptoms, mostly related to the menopausal transition. OBJECTIVE To assess factors associated with chemotherapy-related amenorrhea (CRA) and to evaluate its association with long-term quality of life (QOL). DESIGN, SETTING, AND PARTICIPANTS The prospective,...
Uploaded on: November 6, 2024 -
December 15, 2019 (v1)Journal article
Eribulin mesylate (EM) was recently approved for metastatic breast cancer (MBC) chemotherapy (CT) in late lines by the FDA, with debated results in second line. We evaluated outcomes in breast cancer patients receiving EM as second, third and fourth line in a national real-life cohort of 16,703 consecutive MBC patients initiating their first...
Uploaded on: December 4, 2022 -
2020 (v1)Journal article
Background: Young age is a poor prognostic factor in early stage breast cancer (BC) but its value is less established in metastatic BC (MBC). We evaluated the impact of age at MBC diagnosis on overall survival (OS) across three age groups (<40, 40 to 60 and > 60 years(y)).Methods: ESME MBC database is a national cohort, collecting retrospective...
Uploaded on: December 3, 2022 -
February 2021 (v1)Journal article
Background: High Body mass index (BMI) is a risk factor for breast cancer among postmenopausal women and an adverse prognostic factor in early-stage. Little is known about its impact on clinical outcomes in patients with metastatic breast cancer (MBC).Methods: The National ESME-MBC observational cohort includes all consecutive patients newly...
Uploaded on: December 4, 2022 -
January 2020 (v1)Journal article
The aims of the present study were to describe treatment patterns and survival outcomes in patients with central nervous system metastases (CNSM) selected among metastatic breast cancer (MBC) patients included in a retrospective study from the Epidemiological Strategy and Medical Economics (ESME) MBC cohort.
Uploaded on: December 3, 2022